Article Sidebar
Views pdf: 80
DETERMINATION OF PLASMA MMP-9 LEVELS IN PATIENTS WITH HYPOPHARYNGEAL AND LARYNGEAL CANCER
Main Article Content
Abstract
Objective: This study aimed to determine and evaluate plasma MMP-9 concentrations in patients with hypopharyngeal and laryngeal cancer compared to control groups. Methods: A prospective, controlled, cross-sectional descriptive study with longitudinal follow-up was conducted on 184 cancer patients (57 with hypopharyngeal cancer and 127 with laryngeal cancer), 58 patients in the disease control group (with other laryngeal diseases such as laryngitis or laryngeal fibrosis), and 50 healthy controls. Results: The cancer group consisted predominantly of male patients (97.8%) and had a significantly higher mean age compared to the disease control group (60.7 ± 8.6 vs. 44.3 ± 11.4 years; p<0.001). The median plasma MMP-9 concentration in the cancer group (38.40 ng/mL) was significantly higher than in both the healthy and disease control groups (p<0.05). MMP-9 levels increased progressively with cancer stage, peaking in stage IV (57.15 ng/mL; p<0.05). Patients with invasive tumors and histological grade 3 exhibited significantly higher MMP-9 levels (p<0.05). No statistically significant differences in MMP-9 levels were observed between patients with laryngeal versus hypopharyngeal cancer, with or without lymph node metastasis, or between histological grades 1 and 2. Conclusion: Serum MMP-9 levels were elevated in patients with laryngeal and hypopharyngeal cancer and were associated with disease stage, tumor invasiveness, and histological differentiation. MMP-9 shows potential as a biomarker for assessing disease severity
Article Details
Keywords
MMP-9 level, hypopharyngeal - laryngeal cancer.
References
2. Li X, Gao L, Li H, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis. J Infect Dis. 2013;207(3):479–488.
3. WHO. Global Cancer Observatory: Viet Nam 2022. [Internet]. 2022. Available from: https://gco.iarc.fr/
4. Wang Y, Zhang S, Gao H, Li X, Wang L. Expression and clinical significance of MMP-9 and VEGF in laryngeal squamous cell carcinoma. BMC Cancer. 2023;23(1):781.
5. Zhou Y, Wang J, Zhang X. Prognostic value of MMP-9 in patients with head and neck squamous cell carcinoma: a meta-analysis. PLoS One. 2020;15(3):e0230345.
6. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
7. Benitha A, Haridas R, Kannan S, et al. Evaluation of serum levels of MMP-9 in oral squamous cell carcinoma and its clinicopathological correlation. J Oral Maxillofac Pathol. 2023;27(3):393–401.
8. Chen X, Xu Q. The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. Braz J Otorhinolaryngol. 2021;87(5):521–528.
9. Panda NK, Kaur R, Sharma SC, et al. Serum concentration of MMP-9 as a predictive biomarker for the progression of oral cancer. J Maxillofac Oral Surg. 2024;23(5):1079–1088.
10. Jeengar MK, Patel SS, Patel PD, et al. Stage-specific expression analysis of MMP-2 and MMP-9 in laryngeal carcinoma. J Cancer Res Ther. 2020;16(3):607–614.